Clinical-stage partners Immune-Onc is a private, clinical-stage oncology company with IO-108, IO-202, IO-106, IO-312 and undisclosed programs targeting myeloid checkpoints, presenting opportunities for collaboration or out-licensing in multiple hematologic malignancies and solid tumors.

Strategic collaborations Past and ongoing collaborations, including a clinical trial collaboration with BeiGene to evaluate IO-108 and IO-202 in combination with tislelizumab, indicate a receptive stance toward co-development and licensing deals to accelerate global trials and market access.

Financing momentum With a Series B extension and a total funding level around one hundred forty million dollars, Immune-Onc demonstrates capital readiness to scale partnerships, expand trials, and advance multiple assets toward later-stage development.

Clinical evidence focus IO-202 and IO-108 are advancing in Phase 1b/2 across AML, CMML, solid tumors, and chronic myelomonocytic leukemia, suggesting sales opportunities to support combination strategies, biomarker-driven programs, and investigator-sponsored trials in hematology and oncology.

Market positioning A specialized platform targeting inhibitory receptors on myeloid cells positions Immune-Onc to attract buyers seeking first-in-class or differentiated mechanisms, with potential demand from pharma looking to bolster immuno-oncology portfolios.